Telix Pharmaceuticals (innovations) Pty Limited

This early-stage study tests a radioactive drug called 131I-TLX101 given alongside standard treatments for people with newly diagnosed glioblastoma, an aggressive brain cancer. The main goal is to find a safe dose and check for side effects. About 12 adults who have had surgery f…

This study tests whether adding a radioactive drug (lutetium-177 rosopatamab) to standard treatment helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. About 520 men with PSMA-positive metastatic castration-resistant prostate…

This study tests a new drug, TLX101-Tx, which delivers radiation directly to glioblastoma cells, combined with standard chemotherapy (lomustine) in 50 adults whose brain cancer has returned after initial treatment. The goal is to see if the combination helps control the tumor bet…

This study tests a new drug, 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell renal cell carcinoma that has come back or spread. The trial compares two different doses of the drug to standard single-drug therapy to …

This study tests whether combining two types of scans (PSMA PET and MRI) can find prostate cancer better than the usual methods. About 204 men with suspected prostate cancer will get the combined scan, and results will be checked against tissue samples. The goal is to see if this…

This early-phase study tests a single dose of TLX090-Tx in 33 adults with advanced cancer that has spread to the bones, causing pain. The goal is to see if the drug is safe and can reduce pain. Participants must have at least one painful bone spot and have tried other treatments …